GCC tafamidis pricing is roughly a tenth of the US level, but the absence of a formal NPHC programme and a diagnostic bottleneck, not affordability, caps uptake.
Unlike PNH or SMA, ATTR has no formal NPHC coverage programme in Saudi Arabia. Tafamidis (Vyndaqel), SFDA-registered since 2021 and MOH UAE-registered since 2022, is accessed through cardiologist specialist prescription plus case-by-case MOH or hospital pharmacy committee approval — requiring a complete patient file: echocardiography confirming ATTR-CM, Tc-PYP scintigraphy results, and TTR genetic testing where hereditary ATTR (ATTRv) is suspected. Estimated approval rate at specialist centres is 50-60% of submitted cases. Vutrisiran (Amvuttra), targeting ATTR-PN, remains pre-SFDA-registration in the GCC, with access limited to named-patient compassionate use while Alnylam pursues formal registration.
The economic case for GCC tafamidis is unusually favourable: MOH tender pricing runs SAR 70,000-90,000 per year in Saudi Arabia against a US WAC equivalent of roughly SAR 850,000 — an approximately 90% discount achieved through GCC reference pricing against Portugal and Greece plus direct MOH negotiation. UAE pricing (Dubai MOH tender) runs AED 55,000-75,000 per year. Despite this favourable pricing, uptake is constrained by diagnostics, not cost: individual MOH approval requires Tc-PYP scintigraphy at Perugini grade ≥2 (or biopsy with TTR staining), NT-proBNP/echo confirmation of HFpEF, and eGFR >25 mL/min. Tc-PYP scintigraphy itself is available at fewer than 8 GCC centres, so patients outside those cities cannot complete the diagnostic work-up required for MOH approval without travel, independent of formulary status or price.
GCC ATTR amyloidosis agent access status — 2026
| Drug (Brand / INN) | SFDA / GCC Registration Status | NPHC / MOH Coverage Pathway | GCC Pricing | Key Access Barrier |
|---|---|---|---|---|
| Vyndaqel (tafamidis) | SFDA 2021; MOH UAE 2022 | No formal NPHC programme; case-by-case MOH/hospital pharmacy approval | ~SAR 70,000-90,000/year (~10% of US WAC) | Tc-PYP scintigraphy access (<8 GCC centres) gates diagnosis |
| Amvuttra (vutrisiran) | SFDA registration pending | Named-patient compassionate use only | Not yet tender-priced in GCC | Pre-registration; no formulary pathway yet |
Sources: Pfizer GCC access team data 2023; NPHC programme coverage list 2023; Saudi MOH drug procurement 2023; UAE DHA drug pricing database 2023; GCC Cardiology Society ATTR working group 2023; Pfizer GCC access documentation.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC programme-scope gap analysis for ATTR vs PNH/SMA
- MOH hospital pharmacy committee approval requirements and documented approval rate
Delivers
- GCC tafamidis pricing by market (KSA MOH tender vs Dubai MOH tender)
- reference-pricing mechanism against Portugal/Greece benchmarks
Delivers
- Tc-PYP scintigraphy centre-by-centre GCC availability map
- diagnostic-access commercial strategy for expanding beyond the <8-centre bottleneck
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why NPHC has no formal ATTR-CM coverage programme, unlike PNH or SMA, leaving access to run case-by-case through MOH and hospital pharmacy committees
- How tafamidis's SFDA (2021) and MOH UAE (2022) registrations still translate into cardiologist specialist-prescription-only access
- The complete patient file MOH approval requires: echocardiography confirming ATTR-CM, Tc-PYP scintigraphy, and TTR genetic testing for suspected ATTRv
- Why the estimated approval rate at specialist centres runs only 50-60% of submitted cases despite tafamidis's SFDA registration
- How MOH tender pricing of SAR 70,000-90,000 a year, roughly a 90% discount off the ~SAR 850,000 US WAC equivalent, was set via Portugal/Greece reference pricing
- UAE Dubai MOH tender pricing at AED 55,000-75,000 a year and how it compares with the Saudi MOH tender mechanism
- Why Tc-PYP scintigraphy at Perugini grade ≥2, available at fewer than 8 GCC centres, gates MOH approval regardless of formulary status or price
- How NT-proBNP/echo confirmation of HFpEF and eGFR >25 mL/min requirements compound the diagnostic bottleneck outside major cities
- Why Amvuttra (vutrisiran) for ATTR-PN remains pre-SFDA-registration in the GCC, limited to named-patient compassionate use while Alnylam pursues approval
- What a formal SFDA registration for vutrisiran would need to look like given tafamidis's existing case-by-case approval precedent
- What it would take for NPHC to move ATTR-CM from case-by-case MOH approval to a formal coverage programme, as it has for PNH and SMA
- Why diagnostics, not price, is the binding constraint on formal-programme uptake given tafamidis's already-favourable GCC tender pricing
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment is built from Pfizer GCC access documentation, Saudi MOH and UAE DHA pricing data, and GCC Cardiology Society ATTR working group guidance.
Key sources: Pfizer GCC access team data (2023); NPHC programme coverage list (2023); Saudi MOH drug procurement data (2023); UAE DHA drug pricing database (2023); GCC Cardiology Society ATTR working group documentation (2023).
- Case-by-case MOH approval pathway verified against Pfizer GCC access team data (2023) and NPHC programme coverage list (2023)
- GCC tafamidis pricing verified against Saudi MOH drug procurement data (2023) and UAE DHA drug pricing database (2023)
- Tc-PYP diagnostic centre count verified against GCC Cardiology Society ATTR working group documentation (2023)
Frequently asked questions
Commission this assessment
AXLRx ATTR Amyloidosis Payer & HTA (GCC) is built for market access and pricing teams navigating the absence of a formal NPHC programme, case-by-case MOH approval, and the Tc-PYP diagnostic bottleneck across Saudi Arabia and the UAE. Custom assessment in 72 hours.
Specify indication, GCC payer focus (NPHC/SFDA pathway, MOH tender pricing, PA criteria), and commercial question.
AXLRx analyst confirms GCC market scope (KSA-first or pan-GCC), NPHC/SFDA registration analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.